EBOS Group (EBO.NZ) Azione Prezzo
EBOS Group Prezzo
Negli ultimi 19 anni EBOS Group ha aumentato il fatturato del 21,7% all'anno, raggiungendo 10,38 miliardi AUD. L'utile per azione è cresciuto del 8,9% all'anno negli ultimi 19 anni. Per EBOS Group, il margine netto del 1,7% risulta sostanzialmente stabile rispetto al 1,9% di alcuni anni fa. Al prezzo attuale il rendimento da dividendo è pari a circa il 8,08%. Il payout ratio è pari a circa il 112% degli utili. Il dividendo è cresciuto del 7,8% all'anno negli ultimi 19 anni. Il target di prezzo di consenso a 12 mesi per EBOS Group è 30,91 AUD, circa il 84,5% sopra il prezzo attuale di mercato. Su 13 analisti, 10 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
EBOS Group Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
EBOS Group Azione e analisi azionaria
Domande frequenti sull'azione EBOS Group
The business model of EBOS Group Ltd revolves around its position as a leading distributor of healthcare, laboratory, and pharmaceutical products. EBOS Group Ltd operates through two segments: Healthcare and Animal Care. The Healthcare segment supplies a broad range of medical products to public and private hospitals, pharmacies, and healthcare providers. The Animal Care segment focuses on providing veterinary products and services to veterinarians, farmers, and other animal healthcare professionals. With its robust distribution network and comprehensive product portfolio, EBOS Group Ltd strives to enhance healthcare outcomes and deliver value to its customers in the healthcare and animal care sectors.
EBOS Group Ltd is primarily active in the healthcare and pharmaceutical industries.
The main competitors of EBOS Group Ltd in the market include companies such as Sigma Healthcare Ltd, Australian Pharmaceutical Industries Limited (API), and New Zealand Pharmaceuticals Limited.
EBOS Group Ltd is a leading healthcare and animal care company based in New Zealand and Australia. With a rich history dating back to 1922, EBOS has grown to become a highly reputable player in the industry. Originally established as a pharmaceutical wholesaler, the company expanded its focus to healthcare and animal care through strategic acquisitions and partnerships. Today, EBOS Group Ltd operates across numerous sectors, including medical, dental, hospital, and retail pharmacy, as well as animal care and pet supplies. The company's commitment to delivering innovative solutions, along with its extensive network of partners and customer-centric approach, has contributed to its continued success and growth.
EBOS Group Ltd, a leading provider of healthcare and animal care products, has achieved several significant milestones. Firstly, the company expanded its operations internationally, establishing a strong presence in Australia and New Zealand. Secondly, EBOS made strategic acquisitions, including those of Symbion and Terry White Group, which further strengthened its market position. Additionally, EBOS achieved consistent revenue growth year on year, demonstrating its ability to deliver value to shareholders. Moreover, the company was recognized for its excellence through numerous awards, such as the Deloitte Top 200 Company of the Year. Overall, EBOS Group Ltd has successfully grown its business, expanded its reach, and gained industry recognition, solidifying its position in the market.
EBOS Group Ltd is primarily present in Australia and New Zealand.
EBOS Group Ltd represents values of integrity, collaboration, and excellence in its corporate philosophy. As a leading Australasian distributor of healthcare, medical, and pharmaceutical products, EBOS Group is committed to delivering high-quality solutions and services to its customers. The company's strong emphasis on ethical business practices and customer satisfaction has positioned it as a trusted partner in the healthcare industry. With a focus on continuous improvement and innovation, EBOS Group strives to enhance the well-being of individuals and communities through its diverse range of products and services.
Gli analisti fissano attualmente un prezzo obiettivo medio di 29,38 AUD per l’azione EBOS Group (mediana: 30,91 AUD), pari a +75,5 % rispetto all’ultimo prezzo. Il consenso si basa su 13 giudizi di analisti.
13 analisti valutano attualmente l’azione EBOS Group: 11 raccomandano l’acquisto, 1 la tenuta e 1 la vendita.
Convertita al tasso di cambio attuale, l’azione EBOS Group quota 10,50 EUR (16,75 AUD).
L’azione EBOS Group (EBO.NZ) è quotata su 3 borse, tra cui: ASX (EBO.AX), Frankfurt (EJG.F).
The EBOS Group Limited is a leading distributor of medical and pharmaceutical products in Australia, New Zealand, and Asia. Their business model is based on supplying products to medical facilities, pharmacies, and healthcare providers. The company operates in various sectors, including Healthcare, Animal Care, and Scientific. In the Healthcare sector, the EBOS Group is an important supplier of medical devices and consumables. They offer a wide range of products, ranging from surgical instruments and diagnostic devices to incontinence products and bandages. In the Animal Care sector, EBOS holds an extensive product list of veterinary medicines and supplies. The EBOS Group is one of the largest suppliers of animal medicines in Australia and New Zealand. The company works closely with veterinarians and professionals in animal health to ensure the best possible fulfillment of the needs of pets and livestock. In the Scientific sector, EBOS trades in laboratory equipment, chemicals, and other scientific products. The company also provides services such as calibration, repair, and maintenance of laboratory equipment. The EBOS Group aims to provide its customers with the highest quality and most innovative products and services. The company holds a wide range of products and brands in stock, including its own brands and established brands such as Johnson & Johnson and Roche. The business model of the EBOS Group is based on providing products and services that meet the needs of its customers. The company has established a network of distribution centers throughout Australia, New Zealand, and Asia to ensure that its customers are supplied quickly and effectively. The EBOS Group also has a strong online presence to enable its customers to easily purchase and access their products. The company also utilizes advanced IT systems and technologies to optimize the ordering and delivery process and ensure fast and reliable product delivery. Overall, the business model of the EBOS Group offers a wide range of high-quality products and services for diverse customer needs. The company is well positioned to leverage growth in the Healthcare, Animal Care, and Scientific sectors in Australia, New Zealand, and Asia, and strengthen its position as a leading company in the medical and pharmaceutical industry. Answer: The EBOS Group Limited is a leading distributor of medical and pharmaceutical products in Australia, New Zealand, and Asia. They provide products to medical facilities, pharmacies, and healthcare providers, and operate in the Healthcare, Animal Care, and Scientific sectors. They offer a wide range of products and brands, have a strong online presence, and utilize advanced technology to optimize the ordering and delivery process. The EBOS Group aims to provide high-quality products and services and is well positioned for growth in the industry.
Il fatturato di EBOS Group ammonta a 10,38 miliardi AUD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il profitto di EBOS Group ammonta a 173,31 Mio. AUD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di EBOS Group è attualmente 20,05. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione EBOS Group.
Il rapporto prezzo/fatturato (P/S) di EBOS Group è attualmente 0,33. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione EBOS Group.
Il Quality Score AlleAktien per EBOS Group è 3/10.
L'ISIN di EBOS Group è NZEBOE0001S6. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di EBOS Group è 724635. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di EBOS Group è EBO.NZ. Con questo simbolo di borsa vengono negoziate le azioni EBOS Group in borsa.
Azione EBOS Group
Altre metriche e analisi di EBOS Group in Deep Dive.
La nostra analisi azionaria dell'azione EBOS Group include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di EBOS Group. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: